Glecaprevir/pibrentasvir: Ph III CERTAIN-1 data

Top-line data from 181 patients with chronic HCV genotype 1 infection without cirrhosis not previously treated with DAAs in the first part of the open-label, Japanese Phase III CERTAIN-1 trial